Curis (CRIS) Competitors

86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 9.4% of Bolt Biotherapeutics shares are held by company insiders. Comparatively, 5.8% of Curis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Curis has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

In the previous week, Curis had 8 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 10 mentions for Curis and 2 mentions for Bolt Biotherapeutics. Bolt Biotherapeutics' average media sentiment score of 1.43 beat Curis' score of 1.17 indicating that Bolt Biotherapeutics is being referred to more favorably in the media.

Bolt Biotherapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Curis has a beta of 3.08, suggesting that its stock price is 208% more volatile than the broader market.

Curis has a net margin of -80.29% compared to Bolt Biotherapeutics' net margin of -455.15%. Curis' return on equity of 0.00% beat Bolt Biotherapeutics' return on equity.

Bolt Biotherapeutics currently has a consensus price target of $34.67, suggesting a potential upside of 770.15%. Curis has a consensus price target of $43.00, suggesting a potential upside of 779.35%. Given Curis' higher possible upside, analysts plainly believe Curis is more favorable than Bolt Biotherapeutics.

Amgen has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Amgen presently has a consensus target price of $356.62, suggesting a potential downside of 5.17%. Curis has a consensus target price of $43.00, suggesting a potential upside of 779.35%. Given Curis' higher possible upside, analysts clearly believe Curis is more favorable than Amgen.

In the previous week, Amgen had 28 more articles in the media than Curis. MarketBeat recorded 38 mentions for Amgen and 10 mentions for Curis. Amgen's average media sentiment score of 1.27 beat Curis' score of 1.17 indicating that Amgen is being referred to more favorably in the media.

Amgen has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market. Comparatively, Curis has a beta of 3.08, suggesting that its stock price is 208% more volatile than the broader market.

76.5% of Amgen shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 0.9% of Amgen shares are held by company insiders. Comparatively, 5.8% of Curis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Amgen has a net margin of 20.96% compared to Curis' net margin of -80.29%. Amgen's return on equity of 137.41% beat Curis' return on equity.

In the previous week, Gilead Sciences had 33 more articles in the media than Curis. MarketBeat recorded 43 mentions for Gilead Sciences and 10 mentions for Curis. Curis' average media sentiment score of 1.17 beat Gilead Sciences' score of 1.04 indicating that Curis is being referred to more favorably in the news media.

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by company insiders. Comparatively, 5.8% of Curis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Gilead Sciences has a net margin of 30.99% compared to Curis' net margin of -80.29%. Gilead Sciences' return on equity of 48.19% beat Curis' return on equity.

Gilead Sciences has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, Curis has a beta of 3.08, indicating that its stock price is 208% more volatile than the broader market.

Gilead Sciences currently has a consensus price target of $158.33, suggesting a potential upside of 22.44%. Curis has a consensus price target of $43.00, suggesting a potential upside of 779.35%. Given Curis' higher probable upside, analysts clearly believe Curis is more favorable than Gilead Sciences.

Gilead Sciences has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

30.0% of Curis shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 5.8% of Curis shares are owned by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Vertex Pharmaceuticals has a net margin of 35.51% compared to Curis' net margin of -80.29%. Vertex Pharmaceuticals' return on equity of 23.86% beat Curis' return on equity.

Vertex Pharmaceuticals has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Curis has a beta of 3.08, suggesting that its share price is 208% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

In the previous week, Vertex Pharmaceuticals had 24 more articles in the media than Curis. MarketBeat recorded 34 mentions for Vertex Pharmaceuticals and 10 mentions for Curis. Vertex Pharmaceuticals' average media sentiment score of 1.25 beat Curis' score of 1.17 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Curis currently has a consensus target price of $43.00, suggesting a potential upside of 779.35%. Vertex Pharmaceuticals has a consensus target price of $559.61, suggesting a potential upside of 17.23%. Given Curis' higher possible upside, equities analysts clearly believe Curis is more favorable than Vertex Pharmaceuticals.